・Pfizer scrapped its own obesity drug candidate, Danuglipron, in early 2025, citing risks of liver enzyme elevations. ・The company purchased Metsera in November for up to $10 billion to reignite its ...

When Pfizer CEO Albert Bourla asked his employees to compress years of vaccine development and manufacturing into months, he knew the first reaction would be resistance. Faced with a task that seemed ...